Zilovertamab vedotin (MK 2140) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Early results from the phase 2 waveLINE-004 study.

被引：0

作者：

Ozcan, Muhit

Lee, Seung Tae

Mensah, Felix

Modi, Dipenkumar

Fossa, Alexander

Kim, Won Seog

Paszkiewicz-Kozik, Ewa

Sawalha, Yazeed

Sevindik, Omur Gokmen

Norasetthada, Lalita

Santoro, Armando

Pathiraja, Kumudu

Chakraborty, Samhita

Marinello, Patricia

Lavie, David

机构：

[1] Ankara Univ, Sch Med, Ankara, Turkiye

[2] Univ Maryland Marlene, Baltimore, MD USA

[3] Stewart Green Ebaum Comprehens Canc Ctr, Baltimore, MD USA

[4] Franciscan Hlth, Indiana Blood & & Marrow Transplantat, Indianapolis, IN USA

[5] Karmanos Canc Inst, Detroit, MI USA

[6] Oslo Univ Hosp, Oslo, Norway

[7] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea

[8] Maria Sklodowska Curie Natl Inst Oncol, Warsaw, Poland

[9] Ohio State Univ, James Canc Hosp & Solove Res Inst, Columbus, OH USA

[10] Istanbul Medipol Univ, Int Sch Med, Istanbul, Turkiye

[11] Chiang Mai Univ, Fac Med, Chiang Mai, Thailand

[12] Humanitas Univ, Pieve & IRCCS Humanitas Res Hosp, Humanitas Canc Ctr, Milan, Italy

[13] Merck Co Inc, Rahway, NJ USA

[14] Hadassah Med Ctr, Jerusalem, Israel

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7531

引用

页数：1

共 50 条

[41] Addition of Polatuzumab Vedotin to Bendamustine and Rituximab (BR) Improves Outcomes in Transplant-Ineligible Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Versus BR Alone: Results from a Randomized Phase 2 Study
Sehn, Laurie H.
Herrera, Alex F.
Matasar, Matthew J.
Kamdar, Manali
McMillan, Andrew K.
Kim, Tae Min
Kim, Won Seog
Hertzberg, Mark
Ozcan, Muhit
Penuel, Elicia
Cheng, Ji
Hirata, Jamie M.
Ku, Grace
Flowers, Christopher
BLOOD, 2017, 130
[42] Tafasitamab for the Treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) in the US Real-World Setting
Saverno, Kimberly
Savill, Kristin M. Zimmerman
Feinberg, Bruce
Galvin, John
Pathak, Prathamesh
Gordon, Sarah
Amoloja, Theresa
Llorente, Mae
Epperla, Narendranath
Nastoupil, Loretta J.
BLOOD, 2023, 142
[43] Preferences and Perceptions Regarding Treatment Decision-Making for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Yung, Mallory
Schnell, Frederick
Vukcevic, Mirko
Kurukulasuriya, Nuwan C.
BLOOD, 2021, 138 : 1928 - +
[44] An updated analysis of JULIET, a global pivotal phase 2 trial of tisagenlecleucel in adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL)
Borchmann, P.
Tam, C. S.
Jaeger, U.
McGuirk, J. P.
Holte, H.
Waller, E. K.
Jaglowski, S. M.
Bishop, M. R.
Andreadis, C.
Foley, S. R.
Westin, J. R.
Fleury, I.
Ho, P. J.
Mielke, S.
Salles, G.
Maziarz, R. T.
Anak, Oe
Pacaud, L. B.
del Corral, C.
Awasthi, R.
Agoulnik, S.
Tai, F.
Schuster, S. J.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 36 - 37
[45] Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma
Spurgeon, Stephen E.
Mei, Matthew
Barr, Paul M.
Barrientos, Jacqueline C.
de Vos, Sven
Furman, Richard R.
Patel, Krish
Thompson, Philip A.
Choi, Michael Y.
Kallam, Avyakta
Wang, Sirou
Ogbu, Uzor C.
Nahar, Akash
Wang, Michael L.
BLOOD, 2022, 140 : 6640 - 6641
[46] Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
Matasar, Matthew J.
Haioun, Corinne
Sancho, Juan-Manuel
Viardot, Andreas
Izquierdo, Antonia Rodriguez
Martin, Eva Maria Donato
Garcia-Sancho, Alejandro Martin
Sandoval-Sus, Jose David
Tilly, Herve
Vandenberghe, Elizabeth
Hirata, Jamie
Choudhry, Priya
Chang, Yi Meng
Musick, Lisa
McMillan, Andrew
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[47] POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB (POLA plus BR) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): UPDATED RESULTS OF A PHASE IB/II RANDOMIZED STUDY AND PRELIMINARY RESULTS OF A SINGLE ARM EXTENSION
Pinto, A.
Sehn, L. H.
Hertzberg, M.
Opat, S.
Herrera, A. F.
Assouline, S.
Flowers, C. R.
Kim, T. M.
McMillan, A.
Ozcan, M.
Safar, V.
Salles, G.
Musick, L.
Hirata, J.
Chang, Y. M.
Ku, G.
Matasar, M. J.
HAEMATOLOGICA, 2021, 106 (10) : 69 - 69
[48] Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.
Hawkes, Eliza Anne
Manos, Kate
Chong, Geoffrey
Palmer, Jodie
MacManus, Michael Patrick
Keane, Colm
Scott, Andrew Mark
Shortt, Jake
Ritchie, David
Churilov, Leonid
Johnston, Laura
Witkowski, Tom
Barraclough, Allison Anne
Lee, Sze Ting
Lin, Wendi
Koldej, Rachel
Khor, Richard
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[49] Polatuzumab vedotin (Pola) plus rituximab (R) plus lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.
Diefenbach, Catherine S. Magid
Abrisqueta, Pau
Gonzalez-Barca, Eva
Panizo, Carlos
Perez, Jose Maria Arguinano
Miall, Fiona
Bastos-Oreiro, Mariana
Lopez-Guillermo, Armando
Banerjee, Lalita
McMillan, Andrew
Hirata, Jamie
Musick, Lisa
Saha, Sourish
Croft, Brandon
Seymour, Erlene Kuizon
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[50] Five-Year Efficacy and Safety of Tafasitamab in Patients With Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results From the Phase II L-MIND Study
Duell, Johannes
Abrisqueta, Pau
Andre, Marc
Augustin, Marinela
Gaidano, Gianluca
Gonzalez Barca, Eva
Jurczak, Wojciech
Kalakonda, Nagesh
Liberati, Anna Marina
Maddocks, Kami J.
Menne, Tobias
Nagy, Zsolt
Tournilhac, Olivier
Bakuli, Abhishek
Amin, Aasim
Gurbanov, Konstantin
Salles, Gilles
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S433 - S434

← 1 2 3 4 5 →